the upcoming catalyst of interest revolves around the potential of the company's ED pill gaining over-the-counter status here in the US
would be the first ED pill to get over-the-counter
its a big deal because sales would be enormous
would instantly make PTPI a buyout target
data is looking very good so far that this is a likely outcome
the stock dropped off hard early this year because of the general market, not because of anything to do with the company or its prospects
Insider buying recently at $3/share
offerings recently as high as $3.43/share
under $2 this stock is basically free money for anyone with patience
GLTY
$PTPI
PTPI
Recent PTPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 09:32:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 09:05:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:05:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 10:07:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 10:06:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 10:05:30 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/30/2023 09:07:41 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/30/2023 09:05:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/15/2023 10:11:15 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 10:00:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:00:18 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/19/2023 08:36:46 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/15/2023 09:16:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/15/2023 08:22:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/25/2023 09:08:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2023 09:03:50 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/15/2023 09:01:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:03:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/11/2023 08:31:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 08:41:57 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM